⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5045069 | 0.84 | — | — | |
| SCHEMBL13256027 | 0.78 | — | — | |
| SCHEMBL17931859 | 0.74 | — | — | |
| SCHEMBL12515 | 0.74 | — | — | |
| SCHEMBL9939169 | 0.74 | SMN1; SMN2 (0.34) | — | |
| SCHEMBL178287 | 0.72 | SMN1; SMN2 (0.46) | — | |
| SCHEMBL21732237 | 0.72 | — | — | |
| SCHEMBL21579243 | 0.72 | — | — | |
| SCHEMBL84805 | 0.72 | — | — | |
| SCHEMBL289706 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2002028829-A2 | PEPTIDE DEFORMYLASE INHIBITORS | QUESTCOR PHARMACEUTICALS, INC. (US) | 2002-04-11 | — | — | WO | claimed |
| US-20230321050-A1 | Heterocyclic Compounds and Uses Thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-11547697-B2 | Heterocyclic compounds and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-20190350906-A1 | Heterocyclic Compounds and Uses Thereof | INTELLIKINE, LLC | 2019-11-21 | — | — | US | disclosed |
| EP-2427195-B1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE LLC (US) | 2019-05-01 | — | — | EP | disclosed |
| CN-106459027-B | 6-substituted-3H-1, 3-benzothiazol-2-one compounds as TARP-gamma 8 dependent AMPA receptor antagonists | 伊莱利利公司 | 2019-04-02 | — | — | CN | disclosed |
| EP-2467141-B1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE LLC (US) | 2018-10-31 | — | — | EP | disclosed |
| US-20180042902-A1 | Heterocyclic Compounds and Uses Thereof | INTELLIKINE, LLC | 2018-02-15 | — | — | US | disclosed |
| US-9718815-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2017-08-01 | — | — | US | disclosed |
| US-9682141-B2 | Combination of kinase inhibitors and uses thereof | INTELLIKINE LLC (US) | 2017-06-20 | — | — | US | disclosed |
| EP-2467141-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Intellikine, Inc. (US) | 2012-06-27 | — | — | EP | disclosed |
| WO-2012064973-A2 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. (US) | 2012-05-18 | — | — | WO | disclosed |
| US-20120122838-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2012-05-17 | — | — | US | disclosed |
| EP-2427195-A2 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Intellikine, Inc. (US) | 2012-03-14 | — | — | EP | disclosed |
| WO-2011149937-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE, INC. (US) | 2011-12-01 | — | — | WO | disclosed |
| WO-2011022439-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE, INC. (US) | 2011-02-24 | — | — | WO | disclosed |
| WO-2010129816-A2 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| US-20100105654-A1 | SUBSTITUTED QUINAZOLINONE COMPOUNDS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2010-04-29 | — | — | US | disclosed |
| US-7625909-B2 | Substituted quinazolinone compounds | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2009-12-01 | — | — | US | disclosed |
| US-7368453-B2 | Quinazolinone compounds with reduced bioaccumulation | CHIRON CORPORATION (US) | 2008-05-06 | — | — | US | disclosed |